ArticleInflammation2021
Differential Expression and Copy Number Variation of Gasdermin (GSDM) Family Members, Pore-Forming Proteins in Pyroptosis, in Normal and Malignant Serous Ovarian Tissue.
Article in Inflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Beyond apoptosis: evidence of other regulated cell death pathways in the ovary throughout development and life.Human reproduction update · 2023Pooled it
- GSDME-mediated pyroptosis is essential for the chemotherapeutic effects achieved by combined treatment of temsirolimus and 5-fluorouracil in ovarian carcinoma cells.American journal of translational research · 2026Article
- Immune system, inflammatory response, and regulated cell death in breast cancer research (Review).Oncology reports · 2026Review
- Inflammasome activation contributes to cisplatin resistance in ovarian cancer.Journal of ovarian research · 2025Article
- The role of pyroptosis in ovarian cancer.Discover oncology · 2025Review
- Identification of a Novel Pyroptosis-Related lncRNAs Prognosis Model and Subtypes in Ovarian Cancer.Phenomics (Cham, Switzerland) · 2025Article
- Potential Impact of Climate Change-Induced Alterations on Pyroptotic Cell Death in Animal Cells: A Review.Molecular biotechnology · 2025Review
- Correlation Analysis of Pyroptosis-Related Genes CASP1, NLRP3, AIM2, and NLRP1 With Lung Adenocarcinoma.International journal of genomics · 2025Article
- Inducers and Inhibitors of Pyroptotic Death of Granulosa Cells in Models of Premature Ovarian Insufficiency and Polycystic Ovary Syndrome.Reproductive sciences (Thousand Oaks, Calif.) · 2024Review
- Gasdermins: a dual role in pyroptosis and tumor immunity.Frontiers in immunology · 2024Review
- Gasdermin D: A Potential New Auxiliary Pan-Biomarker for the Detection and Diagnosis of Diseases.Biomolecules · 2023Review
- The implication of pyroptosis in cancer immunology: Current advances and prospects.Genes & diseases · 2023Review
- Pyroptosis and inflammasomes in cancer and inflammation.MedComm · 2023Review
- A Novel pyroptosis-related signature for predicting prognosis and evaluating tumor immune microenvironment in ovarian cancer.Journal of ovarian research · 2023Article
- Role of gasdermin family proteins in cancers (Review).International journal of oncology · 2023Review
- The role of pyroptosis-related lncRNA risk signature in ovarian cancer prognosis and immune system.Discover oncology · 2023Article
- Targeting pyroptosis in breast cancer: biological functions and therapeutic potentials on It.Cell death discovery · 2023Review
- The study of GSDMB in pathogenesis of psoriasis vulgaris.PloS one · 2023Article
- LINC00511/hsa-miR-573 axis-mediated high expression of Gasdermin C associates with dismal prognosis and tumor immune infiltration of breast cancer.Scientific reports · 2022Article
- Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer.Cell death discovery · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Gasdermins (GSDM) are members of a family of pore-forming effector proteins which lead to membrane permeabilization and pyroptosis, a lytic cell death with pro-inflammatory characteristics. Recently, two members of the gasdermin family, gasdermin B (GSDMB) and gasdermin E (GSDME), were shown to suppress tumor growth, through the involvement of cytotoxic lymphocytes. Other studies also reported the important functions of gasdermins in various cancer types including gastric cancer, hepatocarcinoma, and cervix and breast cancer. However, gasdermins have not been previously studied in the context of serous ovarian cancer. Here, we showed that gasdermin D (GSDMD) and gasdermin C (GSDMC) expression increases in serous ovarian cancer; in contrast, the expression of GSDME and PJVK (Pejvakin, DFNB59) is downregulated, compared to healthy ovaries, in multiple independent gene expression datasets. We found that copy number gains are highly frequent (present in approximately 50% of patients) in genes encoding GSDMD and GSDMC in ovarian cancer, in line with their upregulated expression in serous ovarian cancer. Moreover, we observed that the expression of GSDMB and GSDMD, but not of GSDME, is different among several histotypes of epithelial ovarian cancer. Therefore, we propose that differential expression and copy number variations of certain gasdermins might be associated with the development of serous ovarian cancer, in which different members of the family have distinct functions; however, further research is required in in vivo models to understand how changes in gasdermin family members mechanistically contribute to serous ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.